CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Van Meerten Tom; Bouwstra Renee; He Yuan; Janneke de Boer; Kooistra Hilde; Fehrmann Rudolf; Ammatuna Emanuele; Huls Gerwin; Bremer Edwin

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

【24h】

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

机译：CD47表达定义RITUXIMAB在非生发中心B细胞（非GCB）弥漫性大B细胞淋巴瘤（DLBCL）中的疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Van Meerten Tom; Bouwstra Renee; He Yuan; Janneke de Boer; Kooistra Hilde; Fehrmann Rudolf; Ammatuna Emanuele; Huls Gerwin; Bremer Edwin;
展开▼
作者单位

Univ Med Ctr Groningen Hematol Washington DC USA;

Univ Med Centrer Groningen Hematol Groningen Netherlands;

Univ Med Centrer Groningen Hematol Groningen Netherlands;

Univ Med Centrer Groningen Hematol Groningen Netherlands;

Univ Med Centrer Groningen Hematol Groningen Netherlands;

Univ Med Ctr Groningen Med Oncol Groningen Netherlands;

Univ Med Centrer Groningen Hematol Groningen Netherlands;

Univ Med Centrer Groningen Hematol Groningen Netherlands;

Univ Med Ctr Groningen Hematol Washington DC USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL [J] . Bouwstra Renee, He Yuan, de Boer Janneke, Cancer immunology research. . 2019,第10期

机译：CD47表达将Rituximab与切碎的疗效定义在非生发中心B细胞（非GCB）弥漫性大B细胞淋巴瘤患者（DLBCL）中，但不是在GCB DLBCL中
2. A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Younes Anas, Sehn Laurie H., Johnson Peter, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在先前未处理的非生态中心B细胞样（GCB）弥漫性大B细胞的患者中，Ibrutinib Plus Rituximab，环磷酰胺，多柔比星，长春酮和泼尼松（RCHOP）的全球性，随机的安慰剂，环磷酰胺，多柔比星，泼尼松（RCHOP）淋巴瘤（DLBCL）
3. Clinical Significance of BCL2 , C- MYC , and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients [J] . Choo-Yuen Ting, Kian-Meng Chang, Jew-Win Kuan, International Journal of Medical Sciences . 2019,第4期

机译：BCL2，C-MYC和BCL6遗传异常，爱泼斯坦-巴尔病毒感染，CD5蛋白表达，生发中心B细胞/非生发中心B细胞亚型，MYC / BCL2蛋白的共表达和共表达的临床意义弥漫性大B细胞淋巴瘤中MYC / BCL2 / BCL6蛋白的表达：120例患者的临床和病理相关性研究
4. DNA Gene Expression Analysis on Diffuse Large B-Cell Lymphoma (DLBCL)Based on Filter Selection Method with Supervised Classification Method [C] . Alok Kumar Shukla, Pradeep Singh, Manu Vardhan International Conference on Computational Intelligence in Data Mining . 2019

机译：基于滤波选择法的弥漫性大B细胞淋巴瘤（DLBCL）对滤波器选择方法的DNA基因表达分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Clinical Significance of BCL2 C-MYC and BCL6 Genetic Abnormalities Epstein-Barr Virus Infection CD5 Protein Expression Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients [O] . Choo-Yuen Ting, Kian-Meng Chang, Jew-Win Kuan, 2019

机译：BCL2C-MYC和BCL6遗传异常爱泼斯坦-巴尔病毒感染CD5蛋白表达生发中心B细胞/非生发中心B细胞亚型MYC / BCL2蛋白的共表达和共表达的临床意义弥漫性大B细胞淋巴瘤中MYC / BCL2 / BCL6蛋白的表达：120例患者的临床和病理相关性研究
7. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature:a report from the International DLBCL Rituximab-CHOP Consortium Program Study [O] . Hu Shimin, Xu-Monette Zijun Y, Balasubramanyam Aarthi, 2013

机译：CD30表达定义了一个新的弥漫性大B细胞淋巴瘤亚组，具有良好的预后和独特的基因表达特征：国际DLBCL利妥昔单抗-CHOP联合计划研究报告

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

著录项

相似文献

相关主题

期刊订阅